Boswellia (AKBA) vs Low-Dose Naltrexone (LDN)
A side-by-side research comparison of Boswellia (AKBA) and Low-Dose Naltrexone (LDN) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Boswellia (AKBA) | Low-Dose Naltrexone (LDN) |
|---|---|---|
| Full name | Boswellia Serrata Extract (AKBA) | Low-Dose Naltrexone |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | OTC supplement | Off-label prescription |
| Mechanism | AKBA (acetyl-11-keto-beta-boswellic acid) selectively inhibits 5-lipoxygenase (5-LOX), reducing pro-inflammatory leukotrienes. This targets a different inflammatory pathway than NSAIDs (which act on COX), sparing the stomach lining. | Brief nocturnal opioid receptor blockade triggers compensatory upregulation of endogenous opioid production and OGF (opioid growth factor), modulating immune cell proliferation and reducing inflammatory cytokines. |
| Molecular weight | 512.7 Da (AKBA) | 341.40 Da |
| Half-life | ~6 hours (AKBA) | ~4 hours |
| Bioavailability | Low; improved by AKBA-standardized and phytosome forms | ~5-40% oral (first-pass) |
| Typical dose | 100-250 mg AKBA-standardized, 1-2x daily | 1.5-4.5 mg |
| Frequency | 1-2x daily | Nightly at bedtime |
| Route | Oral capsule | Oral capsule (compounded) |
Boswellia (AKBA) reported benefits
- Reduces joint pain and stiffness
- Non-NSAID (stomach-sparing) anti-inflammatory
- Supports gut inflammation (IBD research)
- Cartilage protection
- Anti-inflammatory via 5-LOX inhibition
Low-Dose Naltrexone (LDN) reported benefits
- Immune modulation
- Reduced inflammation
- Chronic pain relief
- Autoimmune support
- Improved mood via endorphins
- Weight loss support
Related comparisons
Research and educational reference only. Not medical advice.